Nanotube bottoms are uniformly etched to produce consistent nanoscale pores.
Pressure from payers for improved adherence is driving the need to innovate novel solutions in drug delivery; with only 61.4% of patients actually taking their medication, non-adherence costs the United States, alone, more than $100B annually. In addition to the pain and compliance issues associated with injections and infusions, the delivery profile is often non-optimal, negatively affecting treatment outcomes. Oral delivery via pills does not have the pain associated with injections and infusions, yet still suffers from poor adherence. Extended release implants address all of these issues head on, and likely improve patient outcomes.
Nano Precision Medical is developing a biocompatible, miniaturized, subdermal implant with the NanoPortalTM membrane to provide long-term, substantially constant-rate delivery of therapeutic macromolecules for up to a year.
Frequent, uncomfortable treatments lead to reduced patient compliance and suboptimal outcomes.
Diminished concentrations between treatments can limit treatment efficacy.
Spikes in concentration immediately following treatments often cause toxicity and undesirable patient side effects.
Clinicians and insurance providers can trust that patients receive their prescribed treatment, maximizing the chance for positive outcomes.
Consistent delivery rates eliminate concentration spikes and diminished concentrations, overcoming the pharmacokinetic inadequacies of standard therapy.
Patients can be confident that they will receive their medication for many months without any need for continual oversight.
Our miniaturized device can be inserted in minutes during a simple, outpatient procedure.
Our potent formulation permits an extended duration of therapy to fit into a compact device.
Biocompatible, titania, nanoporous membrane technology enables constant-rate release without moving parts or electronics.